Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Iovance Biotherapeutics Inc shares valued at $55,200 were purchased by Kirby Daniel Gordon on Jun 05 ’25. At $1.84 per share, Kirby Daniel Gordon acquired 30,000 shares. The insider’s holdings grew to 30,000 shares worth approximately $80100.0 following the completion of this transaction.
Also, Puri Raj K. purchased 5,600 shares, netting a total of over 9,743 in proceeds. Following the buying of shares at $1.74 each, the insider now holds 206,852 shares.
Before that, Vogt Frederick G had added 25,000 shares to its account. In a trade valued at $42,250, the Interim CEO & General Counsel bought Iovance Biotherapeutics Inc shares for $1.69 each. Upon closing the transaction, the insider’s holdings increased to 25,000 shares, worth approximately $1.0 million.
As published in a research note from Goldman on July 15, 2025, Iovance Biotherapeutics Inc [IOVA] has been rated down from a Neutral to a Sell and the price target has been revised to $1. Analysts at UBS downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid May. As of May 12, 2025, Truist has decreased its “Buy” rating to a “Hold” for IOVA. Earlier on May 09, 2025, Citizens JMP downgraded its rating. Their new recommendation was “a Mkt perform” for IOVA stock which previously was a “a Mkt outperform”.
Analyzing IOVA Stock Performance
On last trading session,, Iovance Biotherapeutics Inc [NASDAQ: IOVA] plunged -8.56% to $2.67. The stock’s lowest price that day was $2.57, but it reached a high of $2.98 in the same session. During the last five days, there has been a drop of approximately -32.75%. Over the course of the year, Iovance Biotherapeutics Inc shares have dropped approximately -71.14%.
Support And Resistance Levels for Iovance Biotherapeutics Inc (IOVA)
RSI (Relative Strength Index) is 53.58 on the 14-day chart, showing neutral technical sentiment.
Is Iovance Biotherapeutics Inc subject to short interest?
Stocks of Iovance Biotherapeutics Inc saw a sharp rise in short interest on 2025-07-15 jumping by 7.67 million shares to 98.63 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 90.96 million shares. A jump of 7.78% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.04 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.04.
Which companies own the most shares of Iovance Biotherapeutics Inc (IOVA)?
In terms of Iovance Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 4 in the next 12 months, up nearly 36.99% from the previous closing price of $2.92. Analysts anticipate Iovance Biotherapeutics Inc stock to reach 6 by 2025, with the lowest price target being 2. In spite of this, 8 analysts ranked Iovance Biotherapeutics Inc stock as Buy at the end of 2025. On October 24, 2024, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $17.
